share_log

港股异动 | 药明康德(02359)涨超3% 美众议院计划下周对更新版生物安全法案进行审议

HK stocks surged, wuxi apptec (02359) rose more than 3%. The US House of Representatives plans to review the updated version of the Biosafety Act next week.

Zhitong Finance ·  Sep 4 01:37

Wuxi AppTec (02359) rose more than 3%, up 3.11% to HKD 34.85 at the time of publication, with a turnover of 0.106 billion Hong Kong dollars.

According to the Zhitong Finance APP, Wuxi AppTec (02359) rose more than 3%, up 3.11% to HKD 34.85 at the time of publication, with a turnover of 0.106 billion Hong Kong dollars.

On the news front, according to Cailian Press, it was learned through a search on the website of the United States House of Representatives that the House plans to review the "Biosafety Act" (H.R.8333) next week. According to the latest updated pre-printed version of the "Biosafety Act" (H.R.8333), there have been certain modifications compared to the previous version in terms of the effective date interpretation rules and other aspects. It is reported that in May of this year, the House Oversight and Reform Committee of the United States House of Representatives passed the "Biosafety Act" by a vote of 40 to 1.

In addition, the market has long-awaited the start of the Federal Reserve's interest rate cut cycle. Minsheng Securities pointed out that the trend of order recovery is obvious, Q2 performance has improved on a month-on-month basis, and in the second half of the year, with the addition of expectations of Federal Reserve interest rate cuts, the conversion of H1 new orders, and domestic innovation policy support, the CXO sector's H2 performance is expected to continue its recovery.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment